A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

Phase 2TerminatedNCT00788541

Alcon Research197 enrolled

Overview

The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

197

Conditions

Open-Angle Glaucoma Ocular Hypertension

Interventions

Anecortave Acetate Sterile Suspension, 6 mg/mLDRUG

Administered as an injection into an anterior juxtascleral depot

Anecortave Acetate Sterile Suspension, 3.75 mg/mLDRUG

Administered as an injection into an anterior juxtascleral depot

Anecortave Acetate Sterile Suspension, 96 mg/mLDRUG

Administered as an injection into an anterior juxtascleral depot

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of Open-Angle Glaucoma or Ocular Hypertension for at least 6 months; * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Prior angle surgery in the study eye, severe visual field loss in either eye; * Other protocol-defined exclusion criteria may apply.

Locations (1)

Contact Alcon Call Center For Trial Locations

Fort Worth, Texas, United States

Outcomes

Primary Outcomes

Mean Intraocular Pressure

Time frame: 6 months

Secondary Outcomes

Percent of patients who remain rescue-medication free

Time frame: 6 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.